Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 33 条
  • [1] A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas
    Acs, Geza
    Esposito, Nicole N.
    Kiluk, John
    Loftus, Loretta
    Laronga, Christine
    [J]. MODERN PATHOLOGY, 2012, 25 (04) : 556 - 566
  • [2] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
    Albain, Kathy S.
    Barlow, William E.
    Shak, Steven
    Hortobagyi, Gabriel N.
    Livingston, Robert B.
    Yeh, I-Tien
    Ravdin, Peter
    Bugarini, Roberto
    Boehner, Frederick L.
    Davidson, Nancy E.
    Sledge, George W.
    Winer, Eric P.
    Hudis, Clifford
    Ingle, James N.
    Perez, Edith A.
    Pritchard, Kathleen I.
    Shepherd, Lois
    Gralow, Julie R.
    Yoshizawa, Carl
    Allred, D. Craig
    Osborne, C. Kent
    Hayes, Daniel F.
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 55 - 65
  • [3] Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?
    Allison, K. H.
    Kandalaft, P. L.
    Sitlani, C. M.
    Dintzis, S. M.
    Gown, A. M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 413 - 424
  • [4] Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
    Arpino, G
    Weiss, H
    Lee, AV
    Schiff, R
    De Placido, S
    Osborne, CK
    Elledge, RM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17): : 1254 - 1261
  • [5] Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
    Bardou, VJ
    Arpino, G
    Elledge, RM
    Osborne, CK
    Clark, GM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) : 1973 - 1979
  • [6] The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment
    Bueno-de-Mesquita, J. M.
    Nuyten, D. S. A.
    Wesseling, J.
    van Tinteren, H.
    Linn, S. C.
    van de Vijver, M. J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (01) : 40 - 47
  • [7] Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma
    Chang, James M.
    McCullough, Ann E.
    Dueck, Amylou C.
    Kosiorek, Heidi E.
    Ocal, Idris T.
    Lidner, Thomas K.
    Gray, Richard J.
    Wasif, Nabil
    Northfelt, Donald W.
    Anderson, Karen S.
    Pockaj, Barbara A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S509 - S515
  • [8] Chaudhary Lubna N, 2016, Hematol Oncol Stem Cell Ther, V9, P48, DOI 10.1016/j.hemonc.2015.12.001
  • [9] Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Cui, XJ
    Schiff, R
    Arpino, G
    Osborne, CK
    Lee, AV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7721 - 7735
  • [10] Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
    Dinan, Michaela A.
    Mi, Xiaojuan
    Reed, Shelby D.
    Hirsch, Bradford R.
    Lyman, Gary H.
    Curtis, Lesley H.
    [J]. JAMA ONCOLOGY, 2015, 1 (02) : 158 - 166